ArticleBMC medical imaging2026
Application of a multimodal MRI model integrating radiomics and habitat features for predicting glioma pathology and prognosis.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAccurate grading and prognostic assessment of glioma requires integrating key molecular biomarkers, including IDH mutation status and the Ki-67 proliferation index. However, current radiomics studies often focus on single-task predictions and rely on manual tumor segmentation, which fails to capture intratumoral spatial heterogeneity. This study proposes an automated whole-tumor segmentation-based multimodal MRI approach integrating habitat radiomics to achieve noninvasive, multitask prediction of WHO grade, IDH mutation, Ki-67 labeling index (LI), and 2-year postoperative survival in glioma.
methodsThis retrospective study enrolled 185 patients with pathologically confirmed glioma. Preoperative multimodal MRI - including T1-weighted imaging (T1WI), T2-weighted fluid-attenuated inversion recovery (T2W-FLAIR), and T1-weighted contrast-enhanced imaging (T1W CE) - was acquired for analysis. Using the uAI Research Portal platform, we performed automated whole-tumor segmentation and subsequent feature extraction, deriving 2,264 radiomics features and 61 habitat-based features. Predictive models were developed using multiple machine learning algorithms, and feature selection was rigorously performed within the training folds of a five-fold cross-validation to prevent overfitting. Model performance was evaluated using AUC, accuracy, sensitivity, and specificity, with statistical comparisons conducted performed DeLong's test.
resultsThe habitat model exhibited superior sensitivity in capturing tumor heterogeneity across all four prediction tasks. Building on this, the integrated model combining habitat and conventional radiomics features, achieved the highest overall predictive performance, with AUCs of 0.916 (95% CIs: 0.858-0.975) for glioma grading, 0.877 (95% CIs: 0.828-0.926) for IDH mutation status, 0.859 (95% CIs: 0.788-0.930) for Ki-67 LI, and 0.906 (95% CIs: 0.837-0.974) for 2-year survival prediction, consistently outperforming single-modality models. SHAP interpretability analysis revealed that patient age exhibited strong correlation with tumor grade, IDH mutation status, and Ki-67 LI. Furthermore, tumor grade, IDH status, and Ki-67 LI demonstrated potential predictive value for 2-year postoperative survival.
conclusionsThe automated habitat radiomics framework effectively quantified intratumoral spatial heterogeneity in glioma. When combined with conventional radiomics, it significantly enhanced accuracy in predicting key molecular and clinical endpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.